Recent Developments in Saudi Arabia Pharmaceutical Drugs Industry

Saudi Arabia pharmaceutical industry is constantly evolving with key players employing different strategies to stay ahead. From the launch of new drugs to adoption of advanced technologies like AI, the target industry is witnessing a rapid transformation.

In October 2024, EISAI Saudi Arabia commenced sales and marketing activities for Fycompa and Methylcobal. The company also plans to expand its activities to include Lenvima and anticancer agent Halaven from April 2025.

Established in April 2024, EISAI Saudi Arabia has built an in-house sales system in Saudi Arabia. It is gradually taking over commercial rights for the Eisai products in the nation from local distribution partners.

In February 2024, Alpha Pharma and Boehringer Ingelheim collaborated to localize the production of Boehringer’s Type 2 diabetes medicines in Saudi Arabia. Alpha Pharma will manufacture Boehringer’s Type 2 diabetes medicines, making them more accessible to patients in Saudi Arabia.

The collaboration aims to combat type 2 diabetes in Saudi Arabia and is fully aligned with the nation’s Vision 2030 objectives. It highlights Boehringer Ingelheim’s commitment to localizing drug manufacturing and transferring knowledge and technology to bolster the local pharmaceutical industry.

In July 2023, Lifera, a prominent Saudi Arabia-based biopharmaceutical company, Sanofi, and Arabio signed a MoU to manufacture and supply vaccines in Saudi Arabia. This collaboration aims to boost local manufacturing of vaccines in the nation.

The three companies, under the terms of the MoU, will explore opportunities for collaboration to help advance Saudi Arabia’s vaccine localization strategy. This will not only increase location production of vaccines but also potentially reduce overall vaccine costs.

In December 2024, Mabwell partnered with TABUK Pharmaceutical Manufacturing Company to launch biosimilars in the MENA region. At CPHI Middle East 2024, the company signed a licensing and commercialization agreement with TABUK for its leading biosimilars.

Such developments reflect the industry’s dynamic nature to meet growing demand for novel pharmaceutical drugs in Saudi Arabia. According to Coherent Market Insights (CMI), the Saudi Arabia pharmaceutical drugs industry size is slated to reach around US$ 21 billion in 2030.

Overall pharmaceutical drug demand in the nation will likely increase at a CAGR of 7.6% during the forecast period. This is due to rising burden of chronic diseases, growing demand for affordable medicines, and technological advancements in drug manufacturing.

Initiatives like Vision 2030 are setting a perfect tone for the growth of Saudi Arabian pharmaceutical drugs industry. More and more pharmaceutical companies are expanding their operations in the nation to capitalize on emerging opportunities.

The above-mentioned developments underscore the growth scope Saudi Arabia offers to pharmaceutical giants. From launching new drugs to partnering with other companies, pharmaceutical companies are employing various strategies to strengthen their presence in the Saudi industry. This will play a key role in boosting overall industry growth.

Localization of drug manufacturing is set to reduce dependence on imports. It will also improve accessibility for patients in Saudi Arabia. Companies forming strategic alliances indicate a shift towards a more collaborative yet competitive landscape.